$5.31
+0.71 (+15.43%)
Open$4.60
Previous Close$4.60
Day High$5.65
Day Low$4.60
52W High$46.89
52W Low$20.50
Volume—
Avg Volume471.6K
Market Cap49.13M
P/E Ratio23.09
EPS$1.36
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+579.5% upside
Current
$5.31
$5.31
Target
$36.08
$36.08
$23.71
$36.08 avg
$52.26
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 8.74M | 8.70M | 9.10M |
| Net Income | -76,794 | -87,592 | -73,867 |
| Profit Margin | -0.9% | -1.0% | -0.8% |
| EBITDA | -105,264 | -93,337 | -108,348 |
| Free Cash Flow | -51,137 | -57,721 | -60,543 |
| Rev Growth | +8.7% | -7.3% | +10.0% |
| Debt/Equity | 0.73 | 0.64 | 0.72 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |